Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and meta-analysis presented at the European Scientific Working Group on Influenza (ESWI) virtual conference confirming the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older
SUMMIT, N.J., Dec. 7, 2020 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and meta-analysis presented at the European Scientific Working Group on Influenza (ESWI) virtual conference confirming the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.1 Results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.1 aTIV was comparable to a high-dose TIV for the same outcome.1 Influenza causes significant morbidity and mortality in adults 65 years and older, as demonstrated by higher hospitalization and death rates in most recent years, compared with young, healthy adults.2 Seasonal influenza vaccine effectiveness may be impacted by age-related immune decline in this population, which can result in reduced immune response to standard influenza vaccines.3,4 The MF59® adjuvant included in aTIV is designed to enhance the immune response to the influenza strains contained in the vaccine in adults 65 years and older.5,6,7 The data presented at ESWI 2020 comes from a systematic review and meta-analysis of 16 real-world studies over a period of 20 years that evaluated the effectiveness of vaccination with aTIV relative to non-adjuvanted egg-based influenza vaccines or no vaccine in adults 65 years or older.1 “To have results from a systematic review and meta-analysis provides an additional level of evidence for the benefit of adjuvanted influenza vaccines in older adults who face age-related immune decline,” said Brenda L. Coleman, RN, PhD, Infectious Disease Epidemiologist, Sinai Health System, Toronto; Assistant Professor, Dalla Lana School of Public Health, University of Toronto. The MF59® adjuvant is designed to enhance the immune response by increasing the magnitude and persistence of antibody response and creating more diverse, cross-reactive antibodies.6,7,8 This may be important when there is a mismatch between the virus strains included in the vaccine and the strains circulating in the community.7,9,10,11,12,13 “Adults age 65 years and older are at higher risk for complications from seasonal influenza. At Seqirus, we’re focused on utilizing advanced technology like the MF59® adjuvant to potentially offer better protection against influenza for those most vulnerable, like adults in this age group,” said Gregg Sylvester, MD, Chief Medical Officer at Seqirus. “With both COVID-19 and influenza circulating in the Northern Hemisphere this season, it’s critical that as many people as possible receive an influenza vaccine to protect against the flu, and therefore help to keep pressure off health systems during the continued pandemic.” This MF59®-adjuvanted seasonal influenza vaccine has an extensive clinical legacy, with 155+ million doses distributed over 20+ years* and licensure in 30 countries.14 The quadrivalent formulation of the MF59®-adjuvanted influenza vaccine, which adds an additional B strain to the trivalent formulation, was approved by the U.S. Food and Drug Administration (FDA) in February 2020 and in Europe in March 2020 and is available for the 2020/21 influenza season.15 *Doses distributed globally as of November 2020, including both trivalent and quadrivalent formulations. About the Study The systematic review using Cochrane methods included 21 studies after screening 4,374 peer-reviewed journal articles published between January 1, 1997 and July 15, 2020.1 Of these 21 studies, 16 of these were considered sufficiently comparable to include in one of the meta-analyses.1 Pooled relative vaccine effectiveness (rVE) estimates are presented with their 95% confidence intervals.1 Meta-analysis of studies found that aTIV was effective in reducing general practice visits and hospital admissions (absolute VE).1 Pooled estimates of rVE favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.1 aTIV was comparable to high-dose TIV in averting influenza-related medical encounters.1 Although substantial heterogeneity was observed, estimates for rVE were consistently in favor of aTIV over the standard-dose non-adjuvanted vaccines, with the exception of one study.1 About Seasonal Influenza About Seqirus About CSL For more information visit www.seqirus.com and www.csl.com. Intended Audience Forward-Looking Statements MF59® is a registered trademark of Seqirus UK Limited or its affiliates. US/GLB/FLUD/1120/0036 MEDIA CONTACT Polina Miklush 1Effectiveness of the MF59® -Adjuvanted Trivalent Seasonal Influenza Vaccine Among Adults Aged 65 or Older, a Systematic Review and Meta-analysis. Presented at ESWI 2020. 2Centers for Disease Control and Prevention (CDC). (2019). People 65 years and Older & Influenza. Retrieved from: https://www.cdc.gov/flu/highrisk/65over.htm. Accessed November 2020. 3Monto AS, Ansaldi F, Aspinall R, et al. (2009). Influenza control in the 21st century: Optimizing protection of older adults. Vaccine. 2009;27(37):5043-5053. 4McElhaney JE, Verschoor CP, Andrew MK, et al. (2020). The immune response to influenza in older humans: beyond immune senescence. BMC. 5Frey SE, Aplasca-De Los Reyes MR, Reynales H, et al. (2014). Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32:5027-5034. 6O’Hagan DT, Ott GS, Nest GV, et al. (2013). The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12(1):13-30. 7Banzhoff A, Pellegrini M, Del Giudice G, et al. (2008). MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses. 2008;2(6):243-24. 8O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59—an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341-4348. 9Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006:24(16):3063-3065. 10Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59™-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine. 2008;26(12):1525-1529. 11Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28(25):4123-4129. 12Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027-5034. 13Kavian N, Hachim A, Li APY, et al. Assessment of enhanced influenza vaccination finds that Fluad conveys an advantage in mice and older adults. Clin Transl Immunology. 2020;9(2):e1107. 14Data on file. Seqirus Inc; 2019. 15FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) [package insert]. Holly Springs, NC: Seqirus Inc; 2020. 16CDC. (2019). Key Facts about Influenza (Flu). Retrieved from: https://www.cdc.gov/flu/about/keyfacts.htm. Accessed November 2020. 17CDC. (2020). Key Facts About Seasonal Flu Vaccine. Retrieved from: https://www.cdc.gov/flu/prevent/keyfacts.htm. Accessed November 2020. 18CDC. (2020). 2019-2020 U.S. Flu season: Preliminary burden estimates. Retrieved from: https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm. Accessed November 2020. 19CDC. (2020). Who Needs a Flu Vaccine and When. Retrieved from: https://www.cdc.gov/flu/prevent/vaccinations.htm. Accessed November 2020. View original content:http://www.prnewswire.com/news-releases/seqirus-presents-new-late-breaking-data-at-eswi-2020-highlighting-benefits-of-mf59-adjuvanted-seasonal-influenza-vaccine-301187248.html SOURCE Seqirus | ||
Company Codes: Australia:CSL, OTC-PINK:CSLLY |